- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05500157
Assessment of Treatment With Laparoscopic Fenestration or Aspiration Sclerotherapy for Large Symptomatic Hepatic Cysts (ATLAS)
Assessment of Treatment With Laparoscopic Fenestration or Aspiration Sclerotherapy for Large Symptomatic Hepatic Cysts (ATLAS): a Randomized Clinical Trial.
Patients with large hepatic cysts (> 5cm) may develop symptoms. These can be captured with the polycystic liver disease questionnaire (PLD-Q). Treatment of large hepatic cysts consists of aspiration sclerotherapy or laparoscopic fenestration.
The safety and efficacy of both procedures has been explored in two recent systematic reviews yet no evident conclusion regarding superiority of either procedure could be drawn.
The main objective of the ATLAS trial is to compare laparoscopic fenestration and aspiration sclerotherapy in patients with large symptomatic hepatic cysts on patient-reported outcomes.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Rationale: Patients with large hepatic cysts(>5cm) may develop symptoms due to distention of Glisson's capsule and/or compression on other abdominal organs. Frequently reported symptoms include abdominal pain, early satiety, nausea, and dyspnea. These symptoms can be captured in the disease-specific Polycystic Liver Disease Questionnaire (PLD-Q), a validated instrument. The treatment of symptomatic liver cysts is aimed to improve symptoms and quality of life by reducing cyst volume. There are two procedures available to treat symptomatic liver cysts: percutaneous aspiration sclerotherapy and laparoscopic fenestration.
In aspiration sclerotherapy, fluid is evacuated from the liver cyst and subsequently the cyst lining is exposed to a sclerosing agent for a limited period of time. Sclerotherapy causes temporary recurrence of cyst fluid after drainage, but subsequently results in a steady decrease of cyst volume in the majority of patients.
In laparoscopic fenestration the liver is exposed through laparoscopic surgery. In this procedure the cyst is punctured and drained followed by resection of extra-hepatic cyst wall.
The safety and efficacy of aspiration sclerotherapy and laparoscopic fenestration have been explored in two recent systematic reviews. No evident conclusion could be drawn because of the retrospective study design in the vast majority of the studies and the heterogeneity among these. A randomized controlled trial is warranted to identify the possible differences in safety and efficacy in aspiration sclerotherapy and laparoscopic fenestration.
Hypothesis: The investigators expect patients treated with laparoscopic fenestration to have better clinical outcome; i.e. a lower PLD-Q score, compared to aspiration sclerotherapy, when measured 4 weeks after the procedure. The investigators expect this difference to become smaller over time (after 6 and 12 months), with loss of statistical significance.
Objective: The main objective is to compare laparoscopic fenestration and aspiration sclerotherapy in patients with large symptomatic hepatic cysts on patient-reported outcomes. This information can be used to assess cost-effectiveness in both treatments.
Study design: A prospective, randomized clinical superiority trial in which patients will be randomized 1:1 to one of the treatment arms. Patients will be followed for 1 year.
Study population: All patients ≥18 years who are diagnosed with a dominant, simple hepatic cyst (>5 cm in diameter), that are symptomatic (PLD-Q score ≥20) and have an indication for treatment (both aspiration sclerotherapy and laparoscopic fenestration) are suitable for inclusion in this study. Only patients that are eligible for both treatments can be included in this study. In particular, patients with multiple cysts (>20 cysts of >1.5 cm) will be excluded as surgery leads to more complications in these patients.
Intervention: Patients will be randomly allocated to either aspiration sclerotherapy or laparoscopic fenestration. Both procedures are performed according to the standard Radboudumc protocols. Aspiration sclerotherapy consists of ultrasound-guided, percutaneous drainage of the cyst with subsequent sclerosation with ethanol. Laparoscopic fenestration consists of standard abdominal laparoscopy in which the large cyst(s) are drained and deroofed.
Main study parameters: The main study parameter is the PLD-Q score at 4 weeks after treatment. Secondary parameters are among others: PLD-Q score at baseline, 6 months and 12 months; liver volume (CT) at baseline and 4 weeks; cyst volume (ultrasound) at baseline, 4 weeks, 6 months and 12 months; complications according to Clavien-Dindo; admission duration, recurrence and re-intervention rates.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Joost P.H. Drenth
- Phone Number: +31 24 3619190
- Email: joostphdrenth@cs.com
Study Contact Backup
- Name: Thijs Barten
- Phone Number: +31 24 8186542
- Email: thijs.rm.barten@radboudumc.nl
Study Locations
-
-
Gelderland
-
Nijmegen, Gelderland, Netherlands, 6500 HB
- Recruiting
- Radboudumc University Medical Center
-
Contact:
- Radboudumc University M Center
- Phone Number: +31644107787
- Email: joost.drenth@radboudumc.nl
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥18 years
Hepatic cyst characteristics:
- Large (>5 cm),
- Symptomatic (PLD-Q score ≥20),
- Non-parasitic on imaging (US/CT/MRI)
- Non-neoplastic on imaging (US/CT/MRI)
- Providing informed consent
Exclusion Criteria:
- Clinical indication of a complicated hepatic cyst (cyst rupture or active cyst infection)
- Cyst is not laparoscopically accessible for surgery
- Cyst is not percutaneously (ultrasound-guided) accessible for aspiration
- More than 20 cysts of >1.5 cm
- Age above 75 years
- ASA IV
- ECOG score >1
- Aspiration sclerotherapy or laparoscopic fenestration of hepatic cysts was performed in the last 6 months.
- Severe renal impairment (eGFR < 30 ml/min/1,73 m2)
- Coagulopathy (spontaneous INR >2 or platelet count < 80 x 109/l)
- Radiologic contrast allergy
- Pregnancy
- Any current or prior medical condition that may interfere with the conduct of the study or the evaluation of its results in the opinion of the investigator (e.g. inability to fill out questionnaires).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Aspiration sclerotherapy
Aspiration sclerotherapy is a percutaneous procedure that evacuates fluid from the liver cyst and subsequently exposes cyst lining to a sclerosing agent (e.g.
ethanol, minocycline) for a limited period of time.
|
See arm description
|
Active Comparator: Laparoscopic Fenestration
Laparoscopic fenestration exposes the liver through laparoscopic surgery.
During this procedure the cyst is punctured and drained followed by resection of the extra-hepatic cyst wall
|
See arm description
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PLD-Q 4 weeks
Time Frame: 4 weeks after the procedure
|
Comparison of PLD-Q scores 4 weeks after the procedure, adjusted for baseline PLD-Q score.
|
4 weeks after the procedure
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PLD-Q score 1, 6 and 12 months after intervention
Time Frame: up to 12 months
|
PLD-Q score at 1, 6 and 12 months after intervention, adjusted for baseline
|
up to 12 months
|
PLD-Q invididual symptoms
Time Frame: up to 12 months
|
PLD-Q individual symptom scores at 1, 6 and 12 months after intervention, compared to baseline
|
up to 12 months
|
SF-36 MCS
Time Frame: up to 12 months
|
SF-36 Mental Component Score at 1, 6 and 12 months after intervention, adjusted to baseline
|
up to 12 months
|
SF 36 PCS
Time Frame: up to 12 months
|
SF-36 Physical Component Score at 1, 6 and 12 months after intervention, adjusted to baseline
|
up to 12 months
|
EQ-5D-5L
Time Frame: up to 12 months
|
EQ-5D-5L score at 1, 6 and 12 months after intervention, adjusted to baseline
|
up to 12 months
|
Liver and cyst volume
Time Frame: up to 12 months
|
Liver and cyst volume with CT before and 12 months after the intervention
|
up to 12 months
|
Liver and cyst volume at recurrence
Time Frame: up to 12 months
|
Liver and cyst volume in cases of recurrence of symptoms
|
up to 12 months
|
Cyst volume with US
Time Frame: up to 12 months
|
Cyst volume with ultrasound, at baseline and 1, 6 and 12 months after intervention.
|
up to 12 months
|
Adverse events
Time Frame: up to 12 months
|
Adverse events (according to Clavien-Dindo)
|
up to 12 months
|
Technical success
Time Frame: periprocedural
|
Technical success
|
periprocedural
|
Hospital stay
Time Frame: periprocedural
|
Hospital stay in days
|
periprocedural
|
Re-intervention rates
Time Frame: up to 12 months
|
Re-intervention rates during 12 months follow-up.
|
up to 12 months
|
Cost-effectiveness iPCQ
Time Frame: up to 12 months
|
Cost-effectiveness of both procedures iPCQ 1, 6 and 12 months after intervention, adjusted for baseline
|
up to 12 months
|
Cost-effectiveness iMCQ
Time Frame: up to 12 months
|
Cost-effectiveness of both procedures iMCQ 1, 6 and 12 months after intervention, adjusted for baseline
|
up to 12 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Joost P.H. Drenth, Radboud University Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Kidney Diseases
- Urologic Diseases
- Congenital Abnormalities
- Genetic Diseases, Inborn
- Joint Diseases
- Musculoskeletal Diseases
- Muscular Diseases
- Pathological Conditions, Anatomical
- Musculoskeletal Abnormalities
- Abnormalities, Multiple
- Kidney Diseases, Cystic
- Ciliopathies
- Liver Diseases
- Polycystic Kidney Diseases
- Polycystic Kidney, Autosomal Dominant
- Arthrogryposis
- Cysts
Other Study ID Numbers
- 2020-7134
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Autosomal Dominant Polycystic Kidney
-
Emory UniversityPKD FoundationCompleted
-
Mayo ClinicNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Recruiting
-
Mario Negri Institute for Pharmacological ResearchOtsuka Pharmaceutical Italy S.r.l.CompletedAutosomal Dominant Polycystic Kidney DiseaseItaly
-
Mayo ClinicUniversity of Kansas Medical CenterCompletedAutosomal Dominant Polycystic Kidney DiseaseUnited States
-
CHU de ReimsCompletedAutosomal Dominant Polycystic Kidney DiseaseFrance
-
Otsuka Pharmaceutical Development & Commercialization...CompletedAutosomal Dominant Polycystic Kidney DiseaseUnited States
-
Regional Hospital HolstebroAarhus University HospitalCompletedAutosomal Dominant Polycystic Kidney DiseaseDenmark
-
University Hospital, BrestUnknownAutosomal Dominant Polycystic Kidney DiseaseFrance
-
Federico II UniversityCompletedAutosomal Dominant Polycystic Kidney Disease
-
Kadmon Corporation, LLCTerminatedAutosomal Dominant Polycystic Kidney Disease (ADPKD)United States
Clinical Trials on aspiration sclerotherapy versus laparoscopic fenestration
-
Shanghai First Maternity and Infant HospitalShanghai Tongji Hospital, Tongji University School of Medicine; International...RecruitingOvarian Reserve | Ovarian EndometriomaChina
-
Chonnam National University HospitalNot yet recruiting
-
Sefako Makgatho Health Sciences UniversityCompletedLaparoscopic Surgery | Laparoscopic Entry Technique
-
Institute for the Care of Mother and Child, Prague...University Hospital OstravaRecruitingEndometriosis | EndometriomaCzechia
-
Sohag UniversityRecruitingCancer Colon | Laparoscopic Colectomy | Intracorporeal AnastomosisEgypt
-
Meir Medical CenterUnknownEndometriosis | EndometriomaIsrael
-
Assiut UniversityNot yet recruiting
-
Assiut UniversityNot yet recruiting
-
Zagazig UniversityCompleted
-
Radboud University Medical CenterCompletedSymptomatic Dominant Liver CystNetherlands